Back to search
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Clinicaltrials.gov:
EU CTIS:
#2022-501452-29-00
J&J ID:
#CR109323
Other:
#61186372PANSC2002
Subscribe or share this trial
Trials at a glance
Status
Enrollment complete
Condition
Carcinoma, Non-Small-Cell Lung
Trial type
Interventional
Trial phase
Phase 1
Investigational
product
product
Amivantamab
Cetrelimab
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
May 18, 2023
Trial end date
December 31, 2027
CT.gov ID
#NCT05908734
Countries:
- Brazil,
- Italy,
- Malaysia,
- Poland,
- South Korea,
- Spain,
- Turkey (Türkiye),
- United Kingdom,
- United States
Loading...
Milan, Italy, 20162
Adana, Turkey (Türkiye), 01170
Ankara, Turkey (Türkiye), 06800
Ankara, Turkey (Türkiye), 06800
Orbassano, Italy, 10043
Istanbul, Turkey (Türkiye), 34147
Curitiba, Brazil, 80810 050
Los Alamitos, California, United States, 90720
Verona, Italy, 37134
Belo Horizonte, Brazil, 30110 022
Duarte, California, United States, 91010
Irvine, California, United States, 92618
Ankara, Turkey (Türkiye), 06200
Milan, Italy, 20141
Newcastle, United Kingdom, NE7 7DN
São Paulo, Brazil, 01509 900
Barretos, Brazil, 14784 400
Istanbul, Turkey (Türkiye), 34722
Barcelona, Spain, 08035
Alicante, Spain, 03010
Madrid, Spain, 28041
Barcelona, Spain, 8028
Seville, Spain, 41009
Porto Alegre, Brazil, 91350 200
Salvador, Brazil, 40050-410
Kuching, Malaysia, 93586
Londrina, Brazil, 86015 520
Lublin, Poland, 20 609
London, United Kingdom, W6 8RF
Valencia, Spain, 46009
Houston, Texas, United States, 77030
Izmir, Turkey (Türkiye), 35170
Warsaw, Poland, 02 781
Belo Horizonte, Brazil, 30130 090
Portland, Oregon, United States, 97225
Portland, Oregon, United States, 97213
Sutton, United Kingdom, SM2 5PT
Sakarya, Turkey (Türkiye), 54100
Seoul, South Korea, 06351
Seoul, South Korea, 03080
Seoul, South Korea, 03722
Kuala Lumpur, Malaysia, 59100
Fairfax, Virginia, United States, 22031
Poznan, Poland, 60 569
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
Key links
© Johnson & Johnson and its affiliates 2026
